# Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC

> **NCT06125041** · PHASE2 · RECRUITING · sponsor: **Qianfoshan Hospital** · enrollment: 51 (estimated)

## Conditions studied

- Extensive Small Cell Lung Cancer

## Interventions

- **DRUG:** Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy

## Key facts

- **NCT ID:** NCT06125041
- **Lead sponsor:** Qianfoshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125041, "Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06125041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*